Mhd Al Marrawi, MD
Medical Oncologist
Laryngeal Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Damascus University Faculty of Medicine
Medical School
Reading Hospital Medical Center
Internship
Reading Hospital Medical Center
Residency
Cleveland Clinic Foundation
Fellowship
American Board of Internal Medicine - Hematology
American Board of Internal Medicine - Oncology
PA State Medical License Active through 2018
OH State Medical License Active through 2019
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Al-Marrawi, M. Y.,Saroya, B. S.,Brennan, M. C.,Yang, Z.,Dykes, T. M.,El-Deiry, W. S.; Cancer Biol. Ther.. 2013 Jun 25.
See more >>The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
Al-Marrawi, M. Y.,Rini, B. I.,Harshman, L. C.,Bjarnason, G.,Wood, L.,Vaishampayan, U.,Mackenzie, M.,Knox, J. J.,Agarwal, N.,Al-Harbi, H.,Kollmannsberger, C.,Tan, M. H....; Target Oncol. 2013 Sep.
See more >>Pazopanib for the treatment of renal cancer.
Al-Marrawi, M. Y., Rini, B.; Expert Opin Pharmacother. 2011 May.
See more >>